Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
The Junctional Adhesion Molecule 3 (JAM-3) on Human Platelets is a Counterreceptor for the Leukocyte Integrin Mac-1
- S. Santoso, U. Sachs, +4 authors T. Chavakis
- Biology, Medicine
- The Journal of experimental medicine
- 2 September 2002
Human JAM-3 was identified and described as a novel counterreceptor on platelets for the leukocyte β2-integrin Mac-1 and provides a novel molecular target for antagonizing interactions between vascular cells that promote inflammatory vascular pathologies such as in atherothrombosis. Expand
348 CASES OF SUSPECTED NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
Zwa-NAT was clinically the more severe (14% had intracranial haemorrhages) and responded well to either maternal platelet transfusions or intravenous IgG and most children recovered without specific therapy. Expand
Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients.
- A. Greinacher, B. Farner, H. Kroll, T. Kohlmann, T. Warkentin, P. Eichler
- Thrombosis and haemostasis
- 4 June 2005
HIT-associated thrombosis occurs in a considerable proportion of patients before platelet counts decrease by more than 50%, and the most important risk factors were orthopedic/trauma surgery and the magnitude of platelet count decrease. Expand
European collaborative study of the antenatal management of feto‐maternal alloimmune thrombocytopenia
- J. Birchall, Michael F., Cecile Murphy Kaplan, H. Kroll
- British journal of haematology
- 1 July 2003
The results of this study suggest that the start of therapy can be stratified on the basis of the sibling history of FMAIT, and support the use of maternal therapy as first‐line treatment. Expand
A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
The efficacies of therapeutic doses of danaparoid or lepirudin in preventing death, amputation or new TEC in HIT-patients do not differ largely, but the risk of bleeding seems to be higher in lePirudin treated patients. Expand
Platelet alloantibodies in transfused patients
Patients receiving cellular blood components may form HLA antibodies and platelet‐specific alloantibodies, and these antibodies and allo Antibodies may be related to HLA or platelet-specific antibodies. Expand
A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor α‐chain promoter
- U. Sachs, I. Socher, Christian G Braeunlich, H. Kroll, G. Bein, S. Santoso
- Biology, Medicine
- 1 September 2006
Data indicate that a VNTR promoter polymorphism influences the expression of the FcRn receptor, leading to different IgG‐binding capacities. Expand
348 cases of suspected neonatal alloimmune thrombocytopenia
Indicators favored bolus tocolysis but were not statistically significant: a longer gestational period, fewer infants weighing < 2500 gm, and a lower incidence of respiratory distress syndrome. Expand
First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA.
The HIPA test requires strict quality control measures and using both a sensitive functional assay (HIPA test) and aPF4/heparin ELISA will allow detection of antibodies directed to antigens other than PF4/ heparin complexes as well as detection of IgM and IgA antibodies with PF4/. Expand
Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients.
The findings suggest that inherited platelet GP variations might have an important impact on acute thrombotic disease. Expand